ROCKAWAY, N.J. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke.
BASKING RIDGE, N.J. , June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive
Record full year 2023 net sales of $ 16.0 million increased 87% over $8 .6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J. , March 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc.
Record full year 2022 net sales of $ 8.6 million increased 58 % over $ 5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J. , March 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a
Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalents of $34.7 million Company to host conference call and webcast today, March 10, 2022 , at 4:30 PM EST ROCKAWAY, N.J.
Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019 Further reduced net cash usage to $3.7 million in the fourth quarter 2020 versus $4.1 million in the third quarter 2020 Ended 2020 with cash and cash equivalents of $22.6 million , excluding
Continued growth in VA and U.K. Channels Company to host conference call and webcast today, March 23, 2020 at 4:45 pm ET BASKING RIDGE, N.J. , March 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter 2019
Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018 Company to host conference call and webcast today, March 27 , at 4:30pm ET BASKING RIDGE, N.J. , March 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,
Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore ™ (nVNS) label expansion for migraine prevention Announced initiatives to support the potential use of nVNS for the treatment of symptoms associated with COVID-19 Company to host conference call and webcast today, May
Record first quarter 2023 net sales of $2.8 million , approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023 , at 4:30 PM EDT ROCKAWAY, N.J. , May 03, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic